Novartis AG Management Discusses Q2 2012 Results - Earnings Call Transcript

Novartis AG (NVS)

Q2 2012 Earnings Call

July 19, 2012 8:00 am ET


Joseph Jimenez - Chief Executive Officer

Susanne Schaffert - Head of Oncology - Novartis Pharma Germany

Jonathan Symonds - Chief Financial Officer

David Epstein - Division Head of Novartis Pharmaceuticals

Brian Mcnamara - Division Head of Novartis Otc

Kevin J. Buehler - President, Chief Executive Officer, and Chairman

Andrin Oswald - Division Head of Vaccines & Diagnostics

Jeffrey George - Division Head of Sandoz and Member of Executive Committee


Tim Anderson - Sanford C. Bernstein & Co., LLC., Research Division

Alistair D. Campbell - Berenberg Bank, Research Division

Alexandra Hauber - JP Morgan Chase & Co, Research Division

Matthew Weston - Crédit Suisse AG, Research Division

Naresh Chouhan - Liberum Capital Limited, Research Division

Michael Leuchten - Barclays Capital, Research Division

Andrew C. Weiss - Bank Vontobel AG, Research Division

Seamus Fernandez - Leerink Swann LLC, Research Division

Florent Cespedes - Exane BNP Paribas, Research Division

Andrew S. Baum - Citigroup Inc, Research Division

Peter Verdult - Morgan Stanley, Research Division

Florian Gaiser



Good morning and good afternoon, and welcome to the Novartis Q2 Half Year 2012 Results Conference Call and Live Webcast. [Operator Instructions] The conference is being recorded. [Operator Instructions] With that, I would like to hand over to Mr. Joe Jimenez, CEO of Novartis. Please go ahead, sir.

Joseph Jimenez

Thank you. I'd like to welcome everyone to our second quarter and first-half conference call. With me today on the Novartis end are Jon Symonds, the CFO; David Epstein, Head of Pharma; we have all of the division heads, and we have Tim Wright, who is the Head of Pharma Development, with us. So before we begin, I'd like to ask Susanne Schaffert to read the Safe Harbor statement.

If you liked this article you might like

Novartis CEO Joe Jimenez to Step Down in 2018

FDA Greenlights Novartis' Gene Therapy for Leukemia

Novartis' CAR-T Gene Therapy Receives FDA Approval

Novartis AG, Sirius XM Radio, Coupa Software: 'Mad Money' Lightning Round

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)